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Protein Kinase via Induction of MAPK Phosphatase-1
Otgonzaya Ayush1, Chang-Hoon Lee1, Hae-Kyoung Kim1, Suhn-Young Im2, Baik-Hwan Cho3 and
Hern-Ku Lee1
L-glutamine (Gln) is a nonessential amino acid that is the most abundant amino acid in plasma. Gln has been
reported to have an anti-inflammatory activity that involves deactivation of mitogen-activated protein kinases
(MAPKs) in a MAPK phosphatase (MKP)-1-dependent manner. This study investigated the role of Gln in the
inhibition of DNFB-induced allergic contact dermatitis (CD) in the ears of mice, and specifically the involvement
of Gln in p38 MAPK inhibition. Topical application of Gln or the p38 inhibitor, SB202190, suppressed DNFB-
induced CD. Gln application inhibited DNFB-induced p38 phosphorylation. Western blot analysis revealed that
Gln application resulted in early phosphorylation and protein induction of MKP-1. MKP-1 small interfering RNA
(siRNA), but not control siRNA, abrogated Gln-mediated early phosphorylation, protein induction of MKP-1,
deactivation of p38, and Gln-mediated suppression of CD. The extracellular signal–regulated kinase (ERK)
inhibitor, U0126, blocked Gln-induced MKP-1 phosphorylation and protein induction, as well as Gln suppression
of CD. These results suggest that Gln suppresses DNFB-induced CD via deactivation of p38 MAPK through the
early induction of MKP-1, the negative regulator of p38, in an ERK-dependent manner.
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INTRODUCTION
The pathways of three mitogen-activated protein kinases
(MAPK), extracellular signal–regulated kinase (ERK), c-Jun
N-terminal kinase (JNK), and p38, are activated by many
inflammatory stimuli (Chen et al., 2001). Among them, p38
principally functions in the production of inflammatory
molecules (Kumar et al., 2003; Saklatvala, 2004; Schieven,
2005). Therefore, the p38 pathway is crucial in the production
of a variety of inflammatory response proteins, such as pro-
inflammatory cytokines, chemokines, degradative enzymes,
growth factors, and adhesion molecules (Kumar et al., 2003;
Saklatvala, 2004; Schieven, 2005).
p38 MAPK activation is associated with a set of skin
inflammation events that include hapten-induced contact
dermatitis (CD), UV irradiation–induced dermatitis, and psor-
iatic skin lesion (Takanami-Ohnishi et al., 2002; Hildesheim
et al., 2004; Johansen et al., 2005; Funding et al., 2009). Many
investigators have tried to develop p38 inhibitors, and some
have been tested in clinical trials. However, severe side effects
halted their development (Zhang et al., 2007).
The nonessential amino acid L-glutamine (Gln) is an abun-
dant amino acid in plasma (B600mMl1) (Cynober, 2002) and
is an energy substrate for most cells (Fox et al., 1996;
Encarnacion et al., 1998). Consequently, Gln is important in
multiple ways in the nitrogen- and carbon-skeleton exchange
among different tissues (Kovacevic and McGivan, 1983).
Human clinical trials with several patient populations have
demonstrated that Gln treatment decreases infectious compli-
cations, shortens hospitalization, and decreases hospital costs
(Griffiths et al., 1997). In addition, extensive research in animal
models of endotoxin shock, including severe injury models,
has demonstrated that Gln supplementation improves survival,
enhances immune and gut barrier function, decreases
bacteremia, and inhibits gut mucosal atrophy (Newsholme
et al., 1985; Wischmeyer et al., 2001a).
With regard to the molecular mechanism of Gln anti-
inflammatory activity, we have shown that Gln effectively
protects animals from endotoxin shock and inhibits bronchial
allergic asthma by inhibiting cytoplasmic phospholipase A2
(cPLA2) activity (Kim et al., 2006; Ko et al., 2008), which
specifically releases arachidonic acid from the sn-2 position of
glycerophospholipids to provide the precursor to various
ORIGINAL ARTICLE
1Department of Immunology and Institute for Medical Science, Chonbuk
National University Medical School, Jeonju, Korea; 2Department of Biological
Sciences, College of Natural Sciences, Chonnam National University,
Gwangju, Korea and 3Department of Surgery and Research Institute of Clinical
Medicine, Chonbuk National University Medical School, Jeonju, Korea
Correspondence: Hern-Ku Lee, Department of Immunology, Chonbuk
National University Medical School, Chonju, Chonbuk 561-182, Korea.
E-mail: leeh-k@chonbuk.ac.kr
Received 13 February 2012; revised 10 May 2012; accepted 8 June 2012;
published online 18 October 2012
Abbreviations: CD, contact dermatitis; cPLA2, cytoplasmic phospholipase A2;
ERK, extracellular signal–regulated kinase; ESR, ear swelling response; Gln,
L-glutamine; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein
kinase; MKP-1, MAPK phosphatase-1; PEI, polyethyleneimine; siRNA, small
interfering RNA
& 2013 The Society for Investigative Dermatology www.jidonline.org 723
eicosanoids, such as leukotrienes, prostaglandins, and
platelet-activating factor, which are implicated in a variety
of inflammatory diseases (Kita et al., 2006). As a mechanism of
Gln inhibition of cPLA2, we have recently demonstrated that
Gln deactivates p38 and JNK MAPKs, which is a major
upstream pathway for cPLA2 phosphorylation, by a rapid
induction of MAPK phosphatase (MKP)-1 protein, which
preferentially dephosphorylates p38 and JNK (Ko et al., 2009).
On the basis of these findings, it was of interest to
investigate whether Gln could suppress dermatitis by inhibit-
ing p38. In this study, we explored this possibility using a
murine model of DNFB-induced CD. The results demonstrate
that the topical application of Gln suppresses DNFB-induced
CD by deactivating p38 MAPK via the early induction of
MKP-1.
RESULTS
Gln suppresses DNFB-induced ear inflammation
Gln (4% in saline) was topically applied onto the ears of mice
after DNFB challenge: once at 5 minutes, three times at 5, 10,
and 15 minutes, or five times at 5, 10, 15, 20, and 25 minutes.
Application of DNFB to the ears increased ear swelling
response (ESR) by B80% compared with ears of mice that
were treated with vehicle. One-time application of Gln had
little effect on ESR, but application of Gln three or five times
significantly inhibited DNFB-induced ESR at 24 hours, as well
as at 48 hours (Figure 1a). The inhibition was not evident in
the Ala (five applications) control group. Hematoxylin and
eosin staining of sections revealed the development of strong
inflammatory reactions at the DNFB-challenged sites, which
were characterized by marked spongiosis and extensive
leukocyte infiltration in the swollen dermis (Figure 1b). The
extent of infiltration of leukocytes and swelling were signifi-
cantly lower in Gln-treated mice than that in Ala-treated mice.
Gln, but not Ala, significantly reduced protein levels of the
IFN-g, IL-1b, tumor necrosis factor-a, and IL-5 cytokines in the
ears (Figure 1c). In addition to DNFB, Gln also suppressed
picryl chloride, as well as oxazolone-induced ear inflamma-
tion (Figure 1d and e).
Gln inhibits p38 and JNK phosphorylation, and p38 inhibitor
attenuates DNFB-induced CD
We assessed the kinetics of MAPK phosphorylation in the
DNFB-challenged ears (Figure 2). The three MAPKs, p38, JNK,
and ERK, were phosphorylated by DNFB. p38 and JNK
reached their maximal activities within 30–40 minutes, which
declined thereafter. ERK was also phosphorylated, but in
contrast to p38 and JNK its phosphorylation was sustained at
relatively high levels for up to 80 minutes (Figure 2). Applica-
tion of vehicle only induced a weak phosphorylation. Appli-
cation of Gln once had little effect on the phosphorylation of
p38 and JNK, but application of Gln three or five times
inhibited their phosphorylation, and the inhibition was nearly
complete at 50–60 minutes. The inhibition was not evident in
the Ala control group.
We examined the linkage between MAPKs and DNFB-
induced CD; intraperitoneal administration of the p38 inhi-
bitor, SB202190, significantly attenuated ESR (Figure 3a), ear
inflammation (Figure 3b), and cytokine expression (Figure 3c).
JNK or ERK inhibitor did not show such inhibition. These data
suggest that p38 MAPK has a key role in the DNFB-induced
dermatitis, and that Gln suppresses CD through the inhibition
of p38 phosphorylation.
Gln-induced inhibition of p38 was associated with the early
induction of MKP-1
To gain insight into the molecular mechanism of Gln inhibi-
tion of p38 phosphorylation, we examined the effect of Gln on
MKP-1 protein induction. Western blot analysis revealed that
MKP-1 protein increased from 60 minutes and continued to
rise over 120 minutes and persisted for another 2 hours in
response to DNFB challenge (Figure 4a). The appearance of
MKP-1 protein also correlated with the dephosphorylation of
p38 seen in Figure 2. Gln application resulted in an early
induction of MKP-1. Appearance of MKP-1 as early as
30 minutes was evident in the ears of mice that received more
than three applications of Gln, but not Ala. This Gln-induced
induction of MKP-1 also coincided with a Gln-induced
dephosphorylation of p38 seen in Figure 2. To elucidate the
role of MKP-1 in Gln-induced inhibition of p38 phosphoryla-
tion, we tried to block MKP-1 induction using MKP-1 small
interfering RNA (siRNA). Mice were intravenously adminis-
tered 0.1, 0.2, or 0.4 nmol of MKP-1 siRNA or control siRNA
24 hours before DNFB challenge. MKP-1 siRNA, but not
control siRNA, significantly abrogated the DNFB-mediated
induction of MKP-1 at 0.2 or 0.4 nmol (Figure 4b). In mice
pretreated with 0.2 or 0.4 nmol of MKP-1 siRNA, Gln did not
induce MKP-1 and did not inhibit p38 phosphorylation
(Figure 4c). We examined the effect of Gln in the human
keratinocyte cell line HaCaT. Treatment of the cells with
DNFB resulted in phosphorylation of p38 as early as 5 min-
utes, and addition of Gln at 10 minutes not only depho-
sphorylated p38 at 30 minutes in a dose-dependent manner
(Figure 4d) but also caused an early induction of MKP-1 and
dephosphorylation of p38 (Figure 4e), as seen in an in vivo
study. These data clearly indicate that Gln inhibits phosphor-
ylation of p38 through the early induction of MKP-1.
MKP-1 siRNA attenuates Gln suppression of ear inflammation
By using MKP-1 siRNA, we examined whether the ability of
Gln to induce MKP-1 protein was associated with the
beneficial effect of Gln on CD. Pretreatment of MKP-1 siRNA,
but not control siRNA, abrogated the Gln-mediated suppres-
sion of DNFB-induced ESR (Figure 5a), inflammation
(Figure 5b), and cytokine expression (Figure 5c).
Gln-induced induction of MKP-1 is ERK dependent
MKP-1 is a labile protein that is normally degraded by the
ubiquitin/proteasome pathway; its phosphorylation reduces its
ubiquitination and degradation (Sun et al., 1993; Kyriakis and
Avruch, 2001). ERK is responsible for MKP-1 phosphory-
lation (Brondello et al., 1999). We have previously shown
that Gln-induced MKP-1 induction is ERK dependent by
demonstrating that Gln-induced MKP-1 phosphorylation and
protein induction were blocked by pretreatment of the ERK
inhibitor (Ko et al., 2009) in lipopolysaccharide-treated mice.
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Therefore, we currently assessed whether ERK could exert a
similar role in skin inflammation.
We first verified the efficacy of U0126 to inhibit ERK
phosphorylation (Figure 6a). Topical application of Gln three
times resulted in MKP-1 phosphorylation (Figure 6b). U0126
abrogated not only Gln-induced MKP-1 phosphorylation,
protein induction, and deactivation of p38 (Figure 6c), but
also Gln-induced suppression of DNFB-induced ESR
(Figure 6d) and inflammation (Figure 6e).
DISCUSSION
In this study, we demonstrate that Gln is capable of suppres-
sing DNFB-induced CD by inhibiting p38 MAPK in a MKP-1-
dependent manner. Application of DNFB induced the
phosphorylation of p38 MAPK, and p38 inhibitor, SB202190,
suppressed all the DNFB-induced ESR, inflammatory cell
infiltration, and expression of several proinflammatory cyto-
kines, Th1 and Th2 cytokines in the ears we measured. To
gain clinical relevance, Gln was topically applied after the
challenge of DNFB, thus, Gln inhibits elicitation, but not
induction, phase of contact allergy.
Many inflammatory response proteins, such as proinflam-
matory cytokines, chemokines, degradative enzymes, growth
factors, and adhesion molecules, depend on p38 signaling for
their production (Zhang et al., 2007). Therefore, the abrogation
of the p38 pathway results in diminished production of
inflammatory mediators, which blocks inflammation (Kracht
and Saklatvala, 2002; Kumar et al., 2003; Saklatvala, 2004;
Schieven, 2005; Zarubin and Han, 2005). Furthermore, the
p38 pathway has a regulatory role in the proliferation and
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Figure 1. L-glutamine (Gln) suppresses DNFB-induced contact dermatitis. (a) Ear swelling responses (ESRs) were measured. (b) After measurement of ESR at
24 hours, ear sections from the (A) vehicle, (B) DNFB, (C) DNFBþAla ( 5), (D) DNFBþGln (1), (E) DNFBþGln ( 3), or (F) DNFBþGln (5)-treated group
were stained with hematoxylin and eosin (H&E). (c) Cytokine levels were measured and calculated as picograms of protein per milligram of homogenized tissue.
(d) ESR at 24 hours after challenge with oxazolone (Ox) or picryl chloride (PCl). (e) After measurement of ESR, ear sections from the (A) Ox vehicle, (B) Ox,
(C) OxþGln (5), (D) PCl vehicle, (E) PCl, or (F) PClþGln ( 5)-treated group were stained with H&E. Data in a, c, and d represent the mean±SD of
three independent experiments with five mice per group. *Po0.05; **Po0.01. TNF, tumor necrosis factor. Bar¼ 100mm.
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Figure 3. p38 inhibitor attenuates DNFB-induced contact dermatitis. (a) Mitogen-activated protein kinase inhibitors were injected intraperitoneally (i.p.)
24 hours before the challenge of DNFB. Ear swelling responses (ESRs) were measured at the indicated time points. (b) After measurement of ESR at 24 hours,
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differentiation of dendritic cells (Ardeshna et al., 2000; Arrighi
et al., 2001), T cells (Crawley et al., 1997; Rincon et al., 1998;
Maneechotesuwan et al., 2007), and B cells (Craxton et al.,
1998), all of which contribute to the development of
inflammation. These findings support the view of the crucial
function of the p38 pathway in the regulation of inflammation,
including a set of skin inflammatory diseases, such as hapten-
induced CD, UV irradiation–induced dermatitis, and psoriatic
skin lesions (Takanami-Ohnishi et al., 2002; Hildesheim et al.,
2004; Johansen et al., 2005; Funding et al., 2009). In this
study, we found that p38 inhibitor exerted a suppressive
activity, further supporting the notion that p38 has a key role
in the pathogenesis of DNFB-induced CD.
Topical application of Gln resulted in significant suppres-
sion of DNFB-induced ear inflammation, as well as phosphor-
ylation of p38. At present, Gln-induced inhibition of p38 was
attributed to the early induction of the dual phosphatase MKP-
1 protein. This conclusion arose from two observations. First,
Gln application resulted in a rapid induction of MKP-1, which
coincided with Gln-induced inhibition of p38. Second, MKP-1
siRNA abrogated the ability of Gln not only to induce MKP-1
induction and inhibition of p38, but also to suppress ear
inflammation. These findings might explain our previous
observation that Gln-mediated inhibition of cPLA2 phosphor-
ylation is due to its capability to inhibit the phosphorylation of
MAPKs, which are the major upstream pathways for cPLA2
phosphorylation (Kim et al., 2006; Ko et al., 2008). We have
previously shown that Gln rapidly deactivates p38 by dephos-
phorylating them only when these MAPKs were phosphory-
lated in response to lipopolysaccharide, and this effect of Gln
was mediated by rapid (B5 minutes) phosphorylation and
protein induction of MKP-1 (Ko et al., 2009). Therefore, a
rapid and early induction of MKP-1, resulting in deactivation
of p38 and cPLA2, seems to be a common important
mechanism of the anti-inflammatory activity of Gln. We
found that, in addition to Gln, cysteine and valine were
capable of inducing MKP-1 and inhibiting p38 phosphory-
lation, as well as suppressing ESR (data not shown). These
findings indicate that other amino acids can act as modifiers
in the phosphorylation-associated event. Further studies are
required to address the precise mechanisms underlying the
phenomenon.
MKP-1 was originally identified as an ERK-specific phos-
phatase (Sun et al., 1993; Misra-Press et al., 1995), but has
since been also recognized as being able to dephosphorylate
and inactivate both p38 and JNK MAPKs, its substrate
specificity being dependent on cell type and context
(Franklin and Kraft, 1997; Chi et al., 2006; Hammer et al.,
2006; Zhao et al., 2006). Among the MKPs, in addition to
MKP-1, MKP-5 (Tanoue et al., 1999) and MKP-7 (Masuda
et al., 2001) have also been reported to have specificity for
p38 and JNK. Nevertheless, abrogation of the majority of
activities of Gln by MKP-1 siRNA suggests that MKP-1 appears
to be the critical MKP in this process.
MKP-1 has been reported to be a labile protein that is
normally degraded via the ubiquitin/proteasome pathway. Its
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(C) DNFBþGln ( 3), or (D) DNFBþGln (3)þU0126. Data in a, b, and c are representative of three to five independent experiments with 3–5 mice
per time point per experiment. Data in d represent the mean±SD of three independent experiments with five mice per group. **Po0.01. Bar¼ 100mm.
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phosphorylation reduces its ubiquitination and degradation
(Brondello et al., 1999; Orlowski et al., 2002), and
phosphorylation of MKP-1 is mediated by transient
activation of ERK at the two extreme C-terminal Ser359 and
Ser364, which enhances MKP-1 stabilization without altering
its phosphatase activity (Brondello et al., 1999). We currently
demonstrated that (1) the kinetics of phosphorylation
(Figure 6b) and protein induction of MKP-1 in response to
DNFB challenge are very similar (Figure 4a), and (2) the ERK
inhibitor, U0126, blocked not only Gln-induced MKP-1
phosphorylation and protein induction, but also the suppres-
sive activity of Gln against DNFB-induced CD. These findings,
together with our previous report showing similar results in
lipopolysaccharide-induced septic shock model (Ko et al.,
2009), suggest that Gln induces the early induction of MKP-1
protein by preventing its degradation by inducing MKP-1
phosphorylation in an ERK-dependent manner.
As a result of its function to deactivate p38 MAPK, MKP-1
serves as an important negative regulator of the inflammatory
responses. MKP-1 is induced not only by a number of growth
factors and stresses in multiple cell types (Chen et al., 2002;
Zhao et al., 2005; Chi et al., 2006; Zhao et al., 2006; Hu et al.,
2007), but also by multiple immunosuppressive agents,
including glucocorticoids and anti-inflammatory cytokines,
and this induction partially mediates the inhibitory effects of
these agents on MAPK activation (Abraham et al., 2006).
Induction of MKP-1 by transforming growth factor-b and IL-
10 also contributes to the suppressive effects of these potent
anti-inflammatory cytokines on the expression of genes
encoding proinflammatory mediators (Xiao et al., 2002;
Hammer et al., 2005). Therefore, it appears that the
induction of MKP-1 represents a common mechanism of
immunomodulatory agents.
In summary, it seems clear that Gln exerts strong anti-
inflammatory activity against DNFB-induced CD through the
early induction of MKP-1, resulting in the inhibition of p38
MAPK, probably the most important enzyme in induction of
inflammatory reactions. Given that even the parenteral admin-
istration of Gln as a component of supportive nutritional
therapy is safe (Wischmeyer et al., 2001b; Novak et al., 2002;
Noe´, 2009), Gln targeting p38 could be very useful in a
therapeutic regimen in a variety of skin inflammatory diseases.
MATERIALS AND METHODS
Animals
Female C57BL/6J mice (7–8 weeks old, 16–18 g body weight) were
purchased from the Orient Bio (Gapyeong, Gyounggi, Korea) and
kept in our animal facility for at least 1 week before use. All animal
experiments in this study were conducted using a protocol approved
by the Institutional Animal Care and Use Committee of the Chonbuk
National University Medical School.
Chemicals and reagents
DNFB, 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (oxazolone),
picryl chloride, L-Gln (Biotechnology performance certified,
G-8540), and alanine (Ala) were obtained from Sigma-Aldrich
(St Louis, MO). DNFB was dissolved in acetone:olive oil (3:1). Gln
and Ala were dissolved in saline to reach the final concentration of
4%. SB202190 (p38 inhibitor), SP600125 (JNK inhibitor), and U0126
(MEK1/2 inhibitor) were from Calbiochem (San Diego, CA).
SB202190 (5 mg kg 1) (Kang et al., 2008), SP600125
(12.5 mg kg 1), and U0126 (12.5 mg kg 1) (Ko et al., 2009) were
dissolved with DMSO and injected intraperitoneally 24 hours before
DNFB challenge. The control group received vehicle.
Induction of allergic CD
Mice were sensitized on the shaved back of skin with 100ml of 0.3%
DNFB in acetone:olive oil (3:1) (Takanami-Ohnishi et al., 2002; Yuan
et al., 2010), 50ml of 0.5% oxazolone in acetone:olive oil (4:1)
(Noordegraaf et al., 2010), or 50ml of 5% picryl chloride in
ethanol:acetone (3:1) (Mori et al., 2008). Five days after sensiti-
zation, mice were challenged by painting the inner and outer surfaces
of both sides of each ear with 20ml of 0.3% DNFB, 20ml of 0.3%
oxazolone, or 20ml of 0.5% picryl chloride. Vehicle groups received
acetone:olive oil or ethanol/acetone only.
Measurement of ESR
The thickness of the ears was measured using a No. 7326 thickness
gauge (Mitutoyo, Tokyo, Japan). Percent ESR change was expressed as
follows:
[(value at post-DNFB application value at pre-DNFB applica-
tion)value at pre-DNFB application] 100.
Histological analysis
Twenty-four hours after challenge, mice were anesthetized by
inhalation of diethyl ether. Their ears were removed and immersed
in 10% formaldehyde and then embedded in paraffin and cut into
5-mm-thick sections using a SM2000R microtome (Leica, Jena,
Germany). The ear sections were stained with hematoxylin and eosin.
Cell culture
The human keratinocyte cell line, HaCaT, was cultured in DMEM
with high glucose (Thermo Scientific Hyclone No.: SH30243.02),
supplemented with 10% fetal bovine serum and 1% penicillin–
streptomycin (Invitrogen, Grand Island, NY). The cells were main-
tained at 37 1C in a humidified atmosphere at 5% CO2.
Cytokine ELISA of ear tissues
After DNFB challenge, ear samples were weighed (100 mg) and
homogenized in 1 ml of PhosphoSafe Extraction Reagent (Novagen,
Madison, WI) containing a protease inhibitor cocktail. Homogenates
were then centrifuged at 12,000g for 20 minutes at 4 1C to obtain the
supernatant. IFN-g, IL-1b, tumor necrosis factor-a, and IL-5 levels
were analyzed using ELISA kits (R&D Systems, Minneapolis, MN)
according to the manufacturer’s instructions. Cytokine levels were
calculated as picogram of protein per miligram of homogenized
tissue.
siRNA interference
siRNA strands for mouse MKP-1 and controls were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). In vivo delivery of siRNA
was performed using in vivo-jet polyethyleneimine (PEI) (Polyplus-
transfection SA, Illkirch, France), according to the instructions of the
manufacturer. In brief, MKP-1 siRNA and PEI dissolved in 5% glucose
were mixed in a volume of 200ml for intravenous injection at room
temperature for 20 minutes, and the mixture (0.1, 0.2, or 0.4 nmol)
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was administered 24 hours before DNFB challenge. The mixture
containing control siRNA and PEI dissolved in 5% glucose without
siRNA was used as control. To confirm that the MKP-1 siRNA used
really blocked the synthesis of its target, an immunoblotting analysis
was performed.
Immunoblotting analysis
Mice were killed by cervical dislocation, and ear samples were frozen
in liquid nitrogen and stored in  70 1C until analysis. Ear samples
were homogenized in the Phosphosafe Extraction Reagent (Novagen).
Equal amounts of samples were separated by 10% SDS–PAGE under
reducing conditions, and were then transferred onto polyvinylidene
fluoride membranes (Millipore, Billerica, MA). Membranes were
blocked by incubation for 1 hour at room temperature in 5% skimmed
milk in Tris-buffered saline, followed by a further 2 hours of incuba-
tion with primary antibodies against mouse phospho-ERK, phospho-
JNK, phospho-MKP-1, phospho-p38, ERK, JNK, MKP-1, and p38
(Santa Cruz Biotechnology). Blots were washed for 25 minutes with
five changes of Tris-buffered saline-0.05% Tween 20 solution,
followed by incubation for 1 hour at room temperature with horse-
radish peroxidase–conjugated anti-rabbit IgG antibody (Santa Cruz
Biotechnology). Finally, they were developed in LumiGLO reagent
(Cell Signaling Technology, Danvers, MA).
Statistical analysis
All data are shown as mean±SE of mean. Statistical comparison was
performed using one-way ANOVA followed by the Fisher’s test.
Significant differences between the groups were determined using the
unpaired Student’s t-test. A value of Po0.05 was accepted as an
indication of statistical significance.
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